Jade Biosciences, Inc. (NASDAQ: JBIO) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
16.94
-0.20-1.17%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 8.09% | Shs Outstand | 60.86M | Perf Week | -5.31% |
| Market Cap | 1.03B | Forward P/E | - | EPS next Y | -2.92 | Insider Trans | 0.00% | Shs Float | 52.12M | Perf Month | -24.88% |
| Enterprise Value | 924.34M | PEG | - | EPS next Q | -0.73 | Inst Own | - | Short Float | 19.18% | Perf Quarter | 0.71% |
| Income | -152.79M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 9.18 | Perf Half Y | 20.31% |
| Sales | 0.00 | P/B | 2.35 | EPS next Y | 0.96% | ROA | -32.46% | Short Interest | 9.99M | Perf YTD | 9.79% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -49.11% | 52W High | 28.00 -39.50% | Perf Year | 143.74% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -37.40% | 52W Low | 7.00 142.00% | Perf 3Y | -96.46% |
| Dividend Est. | 2.40 (14.17%) | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 5.60% 5.94% | Perf 5Y | -97.68% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | 97.35% | Oper. Margin | 0.00% | ATR (14) | 1.24 | Perf 10Y | - |
| Dividend Ex-Date | Apr 29, 2025 | Quick Ratio | 14.93 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 31.02 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.93 | EPS Q/Q | 11.63% | SMA20 | -13.86% | Beta | 1.57 | Target Price | 47.83 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | -17.90% | Rel Volume | 3.01 | Prev Close | 17.14 |
| Employees | 55 | LT Debt/Eq | 0.00 | Earnings | Nov 12 | SMA200 | -7.27% | Avg Volume | 976.20K | Price | 16.94 |
| IPO Date | Jun 30, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -19.42% - | Net Debt/EBITDA | 0.68 | Volume | 2,942,224 | Change | -1.17% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-11-26 | Reiterated | Jefferies | $40 → $48 | |
| Jun-15-26 | Initiated | UBS | Buy | $45 |
| Jun-02-26 | Reiterated | Piper Sandler | $55 | |
| Jun-02-26 | Reiterated | Guggenheim | Buy | $32 → $47 |
| May-11-26 | Reiterated | Wedbush | Outperform | $34 |
| May-11-26 | Reiterated | Guggenheim | Buy | $14 → $32 |
| Apr-27-26 | Reiterated | HC Wainwright & Co. | Buy | $25 → $45 |
| Mar-06-26 | Reiterated | Stifel Nicolaus | $19 → $40 | |
| Jan-07-26 | Initiated | H.C | Buy | $25 |
| Oct-09-25 | Initiated | BTIG | Buy | $28 |
Latest News· Times ET
Sep-09-26
Sep-09-2611:17AM
Sep-01-26
Aug-19-26
Aug-11-26
Aug-11-2605:40AM
Aug-10-26
03:00AM
Jul-01-26
Jun-26-26
Jun-26-2607:00AM
Jun-15-26
Jun-15-2604:55AM
Company
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | |
| Gross Profit | 0 | 0 | 0 | — | — | — | |
| Selling, General and Administrative Excl. Other | 20 | 21 | 17 | — | — | — | |
| Research and Development | 93 | 53 | 64 | — | — | — | |
| Other Operating Expense | 1 | 0 | 0 | — | — | — | |
| Operating Income | -114 | -75 | -81 | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -14 | 5 | 6 | — | — | — | |
| Net Income Before Taxes | -127 | -70 | -75 | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | |
| Consolidated Net Income | -127 | -70 | -76 | — | — | — | |
| Net Income From Continuing Operations | -127 | -70 | -76 | — | — | — | |
| Net Income | -127 | -70 | -76 | — | — | — | |
| EPS (Recurring) | -4.06 | -85.26 | -100.38 | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -4.06 | -85.26 | -100.38 | — | — | — | |
| EPS (Diluted) | -4.06 | -85.26 | -100.38 | — | — | — | |
| EBITDA | -127 | -69 | -75 | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | |
| Shares Outstanding | 31 | 1 | 1 | — | — | — | |
| Market Capitalization | 478 | 93 | 792 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Frohlich Tom | Chief Executive Officer | May 16 '25 | Buy | 7.40 | 6,000 | 44,400 | 6,000 | May 19 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.